For KRAS and other genes commonly mutated in CRC (APC, TP53, MLH1, and MSH2), the significance of the presence or absence of a mutation, and in some cases, the specific clinical characteristics associated with commonly recurring mutation hotspots9, are becoming well-understood and can help refine clinical management strategies. Here, TP53 is linked to colorectal carcinoma.